Insider buying last 90 days
No open-market insider purchases were filed for MESO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MESO insider filing, plotted on the chart in Gekko.Open MESO in Gekko
Gekko Brief
AI summaryOct 12 closeMesoblast draws attention this week after reporting RYONCIL net product sales of $115 million for fiscal year 2026, up from $17 million in fiscal year 2025, with total revenue of $120 million for the year. Commentary from Bell Potter frames the stock constructively, citing attractive short-term revenue growth and pivotal clinical events ahead, while separate coverage notes the company has completed patient treatment in its pivotal chronic low back pain trial for rexlemestrocel-L, with top-line results expected around mid-next year, alongside efforts to expand RYONCIL into a broader franchise for adult patients.
MESO closed at $14.27, down 0.1%, sitting below both its 50-day average of $15.73 and its 200-day average of $15.80, with the 50-day below the 200-day. The GekkoIndex reads 61.6, placing the stock in the Accumulation zone. Price sits 37.1% below Gekko Fair Value of $22.69.
No confirmed earnings date appears on the calendar for the next 20 trading days, and no insider, Congress or unusual options activity shows up in the respective 90-day and 30-day windows. Seasonality over this stretch has averaged a 1.8% decline across 5 years, rising in 2 of them, a headwind worth noting given the stock's recent weakness. Separately, consensus from 2 covering analysts, both rated buy, carries a target of $37, implying upside of 159.3% from current levels.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Mesoblast price vs fair value
Close $14.27200-day averageGekko Fair Value $22.69
Mesoblast quick facts
- Market cap
- $1.85B
- P/E ratio
- —
- Forward P/E
- 454.6
- EPS, TTM
- −$0.44
- Revenue, TTM
- $120.3M
- Profit margin
- -47.8%
- Dividend yield
- —
- Beta
- 0.86
- Volume
- 143,760 avg 219,406
- 1-year return
- −26.9%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±10.8%
- 50-day average
- $15.73
- 200-day average
- $15.80
- Next earnings
- —
- Shares outstanding
- 129.9M
Mesoblast swing-trade checklist
Mesoblast scores 2 supportive, 0 mixed and 2 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $14.27 is below the 50-day ($15.73) and 200-day ($15.80) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
61.6, Accumulation
Reading 61.6 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
37.1% below
Price is 37.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskno data
No data
No confirmed report date on the calendar.
See earnings - Seasonalityheadwind
−1.8% on average
From this point in the calendar, the next 20 trading days averaged −1.8% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Mesoblast stock chart and price history
Mesoblast closed at $14.27 on Oct 12, 2026, −26.9% over the past year, inside a 52-week range of $13.05 to $21.50.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.8%
- 3 months
- −14.8%
- 6 months
- −2.9%
- 1 year
- −26.9%
The full MESO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MESO in Gekko
Follow Mesoblast through every session
Put MESO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MESO in GekkoFree for 7 days. No credit card required.
About Mesoblast
Mesoblast works on allogeneic cell-based therapies, meaning treatments built from donor-derived cells rather than a patient's own. It targets a wide range of conditions, among them heart disease, spinal and orthopedic disorders, cancer, blood disorders, and immune and inflammatory illnesses. Its work centers on a regenerative medicine platform built around specialized mesenchymal lineage cells, with several candidates now in Phase III trials, including remestemcel-L for severe graft versus host disease and COVID-related respiratory distress, rexlemestrocel-L for advanced chronic heart failure, and MPC-06-ID for chronic low back pain linked to degenerative disc disease. Another program, MPC-300-IV, is being studied for rheumatoid arthritis that has not responded to biologic treatment and for diabetic kidney disease.
To move these programs forward and reach markets, Mesoblast has formed partnerships with other companies. Tasly Pharmaceutical Group distributes two of its heart-related therapies in China, JCR Pharmaceuticals works with it on treatments for wound healing in epidermolysis bullosa, and Grünenthal collaborates on cell therapy for chronic low back pain.
Mesoblast was founded in 2004 and is headquartered in Melbourne, Australia, with operations also reaching the United States, Singapore, the United Kingdom, and Switzerland. Its shares trade under the ticker MESO.
- Sector
- Health technology
- Website
- mesoblast.com
Mesoblast GekkoIndex: the smart money zone
Mesoblast’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.6, in the Accumulation zone, down 4.3 points over five sessions.
61.6Accumulation
Down 4.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 15 | +3.6% | −1.4% | ||
| Accumulation (current zone) | 207 | +1.0% | +6.3% | ||
| Neutral | 376 | +1.6% | +5.5% | ||
| Distribution | 33 | +12.2% | +8.5% | ||
| Selling | 2 | Too few readings yet | |||
Average MESO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the MESO price, zone by zone.Track MESO in Gekko
Is Mesoblast stock overvalued? Gekko Fair Value
Mesoblast trades 37.1% below Gekko Fair Value of $22.69, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Mesoblast shares are worth, recalculated every trading day.
$22.69
Gekko Fair Value, Oct 10, 2026
37.1% Undervalued
At the end of Aug 2026 the price was 43.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MESO in Gekko
Mesoblast insider and Congress trading
No open-market insider purchases were filed for Mesoblast, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MESO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MESO, plotted on the chart in Gekko.Open MESO in Gekko
Mesoblast earnings: next date and track record
Mesoblast beat the EPS estimate in 4 of its last 8 reports, moving 5% on average across the report.
4 of 8reports beat the EPS estimate
±5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 26, 2026 AI summary
- What they said
- Mesoblast reported RYONCIL net revenues of $115 million for fiscal year 2026, its first full year post-launch, establishing it as the only FDA-approved allogeneic mesenchymal stromal cell product. The company holds 1,100+ patents with protection beyond 2044. Revenue is being reinvested into Phase 3 programs targeting chronic low back pain and inflammatory heart failure, with total addressable markets exceeding $20 billion. Label expansion targets include adult GvHD (3x larger than pediatric market) and Duchenne muscular dystrophy.
- Guidance
- Management is pursuing RYONCIL label expansion into adult GvHD, Duchenne, and other rare inflammatory conditions. Phase 3 blockbuster programs in chronic low back pain and inflammatory heart failure represent markets exceeding $20 billion combined. No specific revenue or EPS targets were provided in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 26, 2026 | −$0.13 est −$0.11 | $68.95M est $53.87M | +5.8% |
| Apr 30, 2026 | −$0.07 est −$0.08 | $34.45M est $29.20M | +1.2% |
| Feb 26, 2026 | −$0.31 est −$0.24 | $51.34M est $53.06M | −6.3% |
| Nov 26, 2025 | −$0.07 est −$0.10 | — | +7.3% |
| Aug 28, 2025 | −$0.32 est −$0.20 | $15.58M est $14.13M | −14.2% |
| Jul 29, 2025 | −$0.43 est −$0.37 | $14.02M est $14.13M | −2.0% |
| Apr 30, 2025 | −$0.21 est −$0.35 | $7.02M est $7.48M | +0.3% |
| Feb 26, 2025 | −$0.04 est −$0.41 | $1.58M est $7.48M | −3.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Mesoblast stock forecast and analyst price targets
Analysts’ average 12-month price target for Mesoblast is $37.00, +159.3% from the last close, from 2 firms rating the stock in the last 90 days.
$37.00consensus 12-month target, +159.3% from the last close
Now $14.27Avg $37.00
Low $35High $39
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 3 | Maxim Group | $35 | +145.3% |
| Aug 27 | Piper Sandler | $39 | +173.3% |
+6.3%average 20-day move after past Accumulation readings
−1.8%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Mesoblast seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Mesoblast averaged −1.8% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.0% | 2 of 5 |
| Next 10 trading days | −0.1% | 2 of 5 |
| Next 15 trading days | −2.7% | 2 of 5 |
| Next 20 trading days | −1.8% | 2 of 5 |
| Next 30 trading days | +1.8% | 2 of 5 |
For scale, MESO’s typical 20-trading-day move in either direction is about 10.8%.
Mesoblast market cap and key statistics
Mesoblast’s market cap is $1.85B and revenue of $120.3M over the last twelve months.
Valuation
- Market cap
- $1.85B
- Forward P/E
- 454.6
- EPS, TTM
- −$0.44
- Gekko Fair Value
- $22.69
Trading
- Volume
- 143,760
- Avg volume, 20 days
- 219,406
- 52-week high
- $21.50
- 52-week low
- $13.05
- Shares outstanding
- 129.9M
Financials
- Revenue, TTM
- $120.3M
- Profit margin
- -47.8%
- Return on equity
- -9.9%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.86
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±10.8%
Mesoblast stock news this week
Coverage of Mesoblast this week reads positive: 4 positive, 4 neutral and 0 negative headlines.
- Mesoblast Reports US$115 Million RYONCIL Net Product Sales in Fiscal Year 2026 Annual ReportKalkine, Oct 12
- Mesoblast Limited Lodges Appendix 4G Corporate Governance Key for Year Ended 30 June 2026Kalkine, Oct 12
- What Are Brokers Saying About Mesoblast (ASX:MSB), Transurban (ASX:TCL) and NextDC (ASX:NXT)?Kalkine Media, Oct 12
- Buy, hold, sell: Mesoblast, Transurban, NextDC sharesThe Motley Fool Australia, Oct 12
- Mesoblast Limited (MESO) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Oct 10
- Is Mesoblast (ASX:MSB) Ready to Turn Ryoncil Into a Franchise?Kalkine Media, Oct 9
Mesoblast stock FAQ
What is Mesoblast’s market cap?
Mesoblast’s market cap is $1.85B at the Oct 12, 2026 close of $14.27, with 129.9M shares outstanding.
What is the Mesoblast stock forecast?
The consensus analyst 12-month price target for Mesoblast is $37.00, +159.3% from the last close. Of the 2 firms that rated the stock in the last 90 days, 2 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Mesoblast stock overvalued or undervalued?
On Gekko’s estimate Mesoblast is undervalued: the Oct 12, 2026 close of $14.27 is 37.1% below Gekko Fair Value of $22.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
What is Mesoblast’s 52-week high and low?
Mesoblast’s 52-week high is $21.50 and its 52-week low is $13.05; it closed at $14.27 on Oct 12, 2026, −26.9% over the past year. Over the last five years the shares peaked at $22.00 on Dec 30, 2024.
Is Mesoblast stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (gekkoindex and fair value) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Mesoblast the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.